RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Grand Pharmaceutical Group Stock

Grand Pharmaceutical Group ROE 2024

Grand Pharmaceutical Group ROE

0.12

Ticker

512.HK

ISIN

BMG210A71016

WKN

A0Q8LD

In 2024, Grand Pharmaceutical Group's return on equity (ROE) was 0.12, a -15.66% increase from the 0.15 ROE in the previous year.

Grand Pharmaceutical Group Aktienanalyse

What does Grand Pharmaceutical Group do?

China Grand Pharmaceutical and Healthcare Holdings Ltd is an innovative company in the healthcare and pharmaceutical industry in China. The company was founded in 1997 and is headquartered in Wuhan, Hubei Province. China Grand Pharma specializes in developing, manufacturing, and distributing high-quality medications, medical devices, and services. The company has multiple subsidiaries involved in various areas of the healthcare and pharmaceutical industry. China Grand Pharma’s main business areas include the production and sale of synthetic drugs, traditional Chinese medicines, biopharmaceuticals, veterinary medicine, and medical devices and equipment. The company has a high level of technological expertise in synthetic drug development and has a team of experienced scientists and researchers. China Grand Pharma has continuously invested in research and development to develop innovative and effective medications that meet the needs of patients in China and worldwide. The traditional Chinese medicine segment is another important area of China Grand Pharma’s business. The company holds a leading position in the market and offers a wide range of products made from natural plant extracts and traditional Chinese medicines. Biopharmaceuticals, based on innovative technologies such as recombinant DNA technology or stem cell research, are another important focus of China Grand Pharma. The company is able to develop and manufacture high-quality biopharmaceuticals that can be used for the prevention and treatment of serious diseases. China Grand Pharma is also a major player in the veterinary medicine market and offers a wide range of products for the health of livestock and pets. The company has a high level of technological expertise and has an extensive portfolio of products for the diagnosis, prevention, and treatment of animal diseases. The company also offers a wide range of medical devices and equipment for healthcare in hospitals and clinics. China Grand Pharma provides a variety of products, from diagnostic instruments to surgical tools. Overall, China Grand Pharmaceutical and Healthcare Holdings Ltd is one of the leading companies in the healthcare and pharmaceutical industry in China. The company has a comprehensive range of products and is able to provide high-quality products and services for a variety of applications and needs. China Grand Pharma is highly committed to researching and developing medications and technologies that can improve healthcare in China and enhance the lives of patients worldwide. The company has a strong presence in the Chinese market and has a well-established distribution infrastructure that allows it to distribute its products and services in China and beyond. Grand Pharmaceutical Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Grand Pharmaceutical Group's Return on Equity (ROE)

Grand Pharmaceutical Group's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Grand Pharmaceutical Group's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Grand Pharmaceutical Group's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Grand Pharmaceutical Group’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Grand Pharmaceutical Group stock

What is the ROE (Return on Equity) of Grand Pharmaceutical Group this year?

The ROE of Grand Pharmaceutical Group this year is 0.12 undefined.

How has the Return on Equity (ROE) of Grand Pharmaceutical Group developed compared to the previous year?

The ROE of Grand Pharmaceutical Group has increased by -15.66% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Grand Pharmaceutical Group?

A high ROE indicates that Grand Pharmaceutical Group generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Grand Pharmaceutical Group?

A low ROE can indicate that Grand Pharmaceutical Group is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Grand Pharmaceutical Group affect the company?

A change in ROE (Return on Equity) of Grand Pharmaceutical Group can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Grand Pharmaceutical Group?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Grand Pharmaceutical Group?

Some factors that can influence Grand Pharmaceutical Group's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Grand Pharmaceutical Group pay?

Over the past 12 months, Grand Pharmaceutical Group paid a dividend of 0.14 HKD . This corresponds to a dividend yield of about 2.69 %. For the coming 12 months, Grand Pharmaceutical Group is expected to pay a dividend of 0.16 HKD.

What is the dividend yield of Grand Pharmaceutical Group?

The current dividend yield of Grand Pharmaceutical Group is 2.69 %.

When does Grand Pharmaceutical Group pay dividends?

Grand Pharmaceutical Group pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Grand Pharmaceutical Group?

Grand Pharmaceutical Group paid dividends every year for the past 8 years.

What is the dividend of Grand Pharmaceutical Group?

For the upcoming 12 months, dividends amounting to 0.16 HKD are expected. This corresponds to a dividend yield of 3.02 %.

In which sector is Grand Pharmaceutical Group located?

Grand Pharmaceutical Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Grand Pharmaceutical Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Grand Pharmaceutical Group from 6/27/2024 amounting to 0.26 HKD, you needed to have the stock in your portfolio before the ex-date on 6/6/2024.

When did Grand Pharmaceutical Group pay the last dividend?

The last dividend was paid out on 6/27/2024.

What was the dividend of Grand Pharmaceutical Group in the year 2023?

In the year 2023, Grand Pharmaceutical Group distributed 0.11 HKD as dividends.

In which currency does Grand Pharmaceutical Group pay out the dividend?

The dividends of Grand Pharmaceutical Group are distributed in HKD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Grand Pharmaceutical Group

Our stock analysis for Grand Pharmaceutical Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Grand Pharmaceutical Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.